Association of visceral obesity indicators with prostate cancer: a cross-sectional study from Xinjiang

  • 0College of Public Health, Xinjiang Medical University, Urumqi, China.

|

|

Summary

This summary is machine-generated.

Visceral obesity indicators like VAI and CMI are linked to increased prostate cancer risk. These metrics show promise as potential biomarkers for assessing prostate cancer risk.

Area Of Science

  • Urology
  • Oncology
  • Metabolic Syndrome

Background

  • Prostate cancer (PCa) risk is linked to obesity, particularly visceral obesity.
  • Existing visceral obesity indices (VAI, CMI, LAP) have underexplored associations with PCa.
  • This study examines the relationship between VAI, CMI, LAP, and PCa risk.

Purpose Of The Study

  • To investigate the association between visceral adiposity index (VAI), cardiometabolic index (CMI), and lipid accumulation product (LAP) and prostate cancer (PCa) risk.
  • To evaluate the predictive efficacy of these obesity indicators for PCa.
  • To assess the robustness and clinical utility of VAI and CMI as potential PCa biomarkers.

Main Methods

  • Cross-sectional study of 730 participants (102 PCa patients, 102 controls) using propensity score matching.
  • Calculation of VAI, CMI, and LAP from anthropometric and biochemical data.
  • Logistic regression, restricted cubic spline (RCS), and ROC curve analyses to assess associations and predictive values.

Main Results

  • VAI, CMI, and LAP were significantly higher in PCa patients compared to controls.
  • Positive associations were found between VAI, CMI, LAP, and PCa risk, with VAI and CMI showing robust associations.
  • Higher quartiles of VAI, CMI, and LAP correlated with increased PCa risk (e.g., OR for Q4 VAI: 9.07).
  • RCS analysis revealed nonlinear associations for VAI and CMI, and linear for LAP.
  • ROC analysis indicated moderate predictive values (AUCs: VAI=0.721, CMI=0.711, LAP=0.593).

Conclusions

  • Visceral obesity indicators, specifically VAI and CMI, are closely associated with prostate cancer.
  • VAI and CMI demonstrate good predictive value and robustness for assessing PCa risk.
  • These indices can serve as potential biomarkers for prostate cancer risk assessment.